RU2015128265A - Способы лечения зуда - Google Patents
Способы лечения зуда Download PDFInfo
- Publication number
- RU2015128265A RU2015128265A RU2015128265A RU2015128265A RU2015128265A RU 2015128265 A RU2015128265 A RU 2015128265A RU 2015128265 A RU2015128265 A RU 2015128265A RU 2015128265 A RU2015128265 A RU 2015128265A RU 2015128265 A RU2015128265 A RU 2015128265A
- Authority
- RU
- Russia
- Prior art keywords
- antipruritic
- subject
- administered
- agent
- day
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 21
- 208000003251 Pruritus Diseases 0.000 title claims 13
- 239000003908 antipruritic agent Substances 0.000 claims 15
- 230000001139 anti-pruritic effect Effects 0.000 claims 6
- 230000007803 itching Effects 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 3
- 206010062237 Renal impairment Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical group [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 claims 2
- 208000037911 visceral disease Diseases 0.000 claims 2
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010058130 Asteatosis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010037083 Prurigo Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 206010067409 Trichophytosis Diseases 0.000 claims 1
- 206010060875 Uraemic pruritus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- 229960001513 nalbuphine hydrochloride Drugs 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 231100000857 poor renal function Toxicity 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- 238000006748 scratching Methods 0.000 claims 1
- 230000002393 scratching effect Effects 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737488P | 2012-12-14 | 2012-12-14 | |
| US13/715,625 US8637538B1 (en) | 2012-12-14 | 2012-12-14 | Methods for treatment of pruritis |
| US13/715,625 | 2012-12-14 | ||
| US61/737,488 | 2012-12-14 | ||
| PCT/US2013/075096 WO2014093871A1 (en) | 2012-12-14 | 2013-12-13 | Methods for treating pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015128265A true RU2015128265A (ru) | 2017-01-25 |
Family
ID=50935003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128265A RU2015128265A (ru) | 2012-12-14 | 2013-12-13 | Способы лечения зуда |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2931279B1 (enExample) |
| JP (4) | JP2016506398A (enExample) |
| KR (3) | KR20150093702A (enExample) |
| CN (2) | CN110585209A (enExample) |
| AU (2) | AU2013359017B2 (enExample) |
| BR (1) | BR112015013984A2 (enExample) |
| CA (1) | CA2892393C (enExample) |
| ES (1) | ES2984559T3 (enExample) |
| MX (1) | MX2015007518A (enExample) |
| NZ (1) | NZ708371A (enExample) |
| RU (1) | RU2015128265A (enExample) |
| WO (1) | WO2014093871A1 (enExample) |
| ZA (2) | ZA201504229B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| JP2016506398A (ja) * | 2012-12-14 | 2016-03-03 | トレビ セラピューティクス インコーポレイテッド | そう痒の処置法 |
| WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| TW201725041A (zh) * | 2016-01-04 | 2017-07-16 | 懷特生技新藥股份有限公司 | 治療皮膚癢之醫藥組合物 |
| CN105560202B (zh) * | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
| CA3017374A1 (en) * | 2016-03-21 | 2017-09-28 | Trevi Therapeutics, Inc. | Treatment of uremic pruritus |
| WO2018081273A1 (en) * | 2016-10-25 | 2018-05-03 | Trevi Therapeutics, Inc. | Treatment of prurigo nodularis |
| KR102329377B1 (ko) * | 2017-02-03 | 2021-11-19 | 가부시키가이샤 도요 신야쿠 | 고형 제제 |
| CN118512451A (zh) * | 2018-07-23 | 2024-08-20 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1535687A (zh) * | 1996-11-25 | 2004-10-13 | ������������ʽ���� | 止痒药物 |
| US20030054030A1 (en) * | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
| US6703398B2 (en) * | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
| LT2425821T (lt) * | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
| CA2566217A1 (en) * | 2004-06-03 | 2005-12-15 | Jonathan J. Burbaum | Pharmaceutical compositions for the treatment of pruritus |
| CA2620224C (en) | 2005-08-24 | 2015-11-24 | Penwest Pharmaceuticals Company | Sustained release formulations of nalbuphine |
| US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| FR2963889B1 (fr) * | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
| JP2016506398A (ja) * | 2012-12-14 | 2016-03-03 | トレビ セラピューティクス インコーポレイテッド | そう痒の処置法 |
-
2013
- 2013-12-13 JP JP2015548006A patent/JP2016506398A/ja active Pending
- 2013-12-13 NZ NZ708371A patent/NZ708371A/en unknown
- 2013-12-13 BR BR112015013984A patent/BR112015013984A2/pt not_active Application Discontinuation
- 2013-12-13 KR KR1020157015561A patent/KR20150093702A/ko not_active Ceased
- 2013-12-13 RU RU2015128265A patent/RU2015128265A/ru not_active Application Discontinuation
- 2013-12-13 CA CA2892393A patent/CA2892393C/en active Active
- 2013-12-13 CN CN201910603708.9A patent/CN110585209A/zh active Pending
- 2013-12-13 EP EP13863494.4A patent/EP2931279B1/en active Active
- 2013-12-13 WO PCT/US2013/075096 patent/WO2014093871A1/en not_active Ceased
- 2013-12-13 AU AU2013359017A patent/AU2013359017B2/en active Active
- 2013-12-13 KR KR1020217012252A patent/KR20210050585A/ko not_active Ceased
- 2013-12-13 CN CN201380072542.3A patent/CN104981246A/zh active Pending
- 2013-12-13 MX MX2015007518A patent/MX2015007518A/es unknown
- 2013-12-13 ES ES13863494T patent/ES2984559T3/es active Active
- 2013-12-13 KR KR1020227010137A patent/KR20220044385A/ko not_active Ceased
-
2015
- 2015-06-11 ZA ZA2015/04229A patent/ZA201504229B/en unknown
-
2018
- 2018-08-09 AU AU2018214098A patent/AU2018214098B2/en active Active
-
2019
- 2019-04-04 JP JP2019071738A patent/JP6823857B2/ja active Active
- 2019-09-26 ZA ZA2019/06339A patent/ZA201906339B/en unknown
-
2020
- 2020-10-27 JP JP2020179395A patent/JP7072280B2/ja active Active
-
2022
- 2022-04-27 JP JP2022072885A patent/JP2022105095A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215541A1 (en) | 2016-09-02 |
| ZA201906339B (en) | 2021-07-28 |
| AU2013359017B2 (en) | 2018-05-10 |
| CA2892393C (en) | 2021-06-08 |
| MX2015007518A (es) | 2016-03-01 |
| CN110585209A (zh) | 2019-12-20 |
| JP7072280B2 (ja) | 2022-05-20 |
| NZ708371A (en) | 2020-05-29 |
| AU2018214098A1 (en) | 2018-08-30 |
| KR20210050585A (ko) | 2021-05-07 |
| JP6823857B2 (ja) | 2021-02-03 |
| AU2018214098B2 (en) | 2019-04-18 |
| JP2021020947A (ja) | 2021-02-18 |
| WO2014093871A1 (en) | 2014-06-19 |
| CN104981246A (zh) | 2015-10-14 |
| ZA201504229B (en) | 2021-07-28 |
| JP2016506398A (ja) | 2016-03-03 |
| EP2931279B1 (en) | 2024-03-20 |
| JP2019131588A (ja) | 2019-08-08 |
| KR20220044385A (ko) | 2022-04-07 |
| BR112015013984A2 (pt) | 2017-07-11 |
| CA2892393A1 (en) | 2014-06-19 |
| AU2013359017A1 (en) | 2015-06-11 |
| ES2984559T3 (es) | 2024-10-29 |
| EP2931279A4 (en) | 2016-05-11 |
| KR20150093702A (ko) | 2015-08-18 |
| JP2022105095A (ja) | 2022-07-12 |
| EP2931279A1 (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017101102A (ru) | Способы лечения зуда | |
| JP2016506398A5 (enExample) | ||
| US20240245646A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| JP2017517553A5 (enExample) | ||
| DD244293A5 (de) | Verfahren zur herstellung eines arzneimittels | |
| US20230000866A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| KR20210050585A (ko) | 소양증을 치료하는 방법 | |
| JP2022525202A (ja) | 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| US20170216277A1 (en) | Therapeutic use of nalbuphine without aquaretic effects | |
| Kamei et al. | A novel Nav1. 7, Nav1. 8, and Nav1. 9 blocker, ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins | |
| US20050043274A1 (en) | Pharmaceutical compositions and methods for lowering blood pressure and pulse rate | |
| JP2019509309A5 (enExample) | ||
| US20110008431A1 (en) | Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia | |
| WO2010110428A1 (ja) | 掻痒の予防及び／または治療剤 | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| KR102900177B1 (ko) | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 | |
| MX2007012052A (es) | Composiciones y sales dermatologicas para el tratamiento de enfermedades dermatologicas. | |
| US10463643B2 (en) | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea | |
| RU2388474C2 (ru) | Применение производного дигидроимидазопиразина для лечения или предупреждения боли | |
| CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
| JP2017114816A (ja) | 止痒剤 | |
| HK40041872A (en) | Method for preventing and/or treating aging-associated cognitive impairment | |
| JP2007186477A (ja) | 神経因性疼痛治療剤 | |
| US9284281B2 (en) | Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161214 |